Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3704809 | 0.84 | KDM4E (0.59) | KDM4EMAPTPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL30134679 | 0.83 | MAPT (0.61) | KDM4EMAPTPOLBALDH1A1GAA | |
| SCHEMBL787766 | 0.83 | MAPT (0.61) | KDM4EMAPTPOLBALDH1A1GAA | |
| SCHEMBL3698715 | 0.83 | KDM4E (0.51) | KDM4EMAPTPOLBALDH1A1GAA | |
| SCHEMBL787535 | 0.81 | MAPT (0.56) | KDM4EMAPTALDH1A1PPARGSMN1; SMN2 | |
| SCHEMBL30777576 | 0.81 | MAPT (0.56) | KDM4EMAPTALDH1A1PPARGSMN1; SMN2 | |
| SCHEMBL3703417 | 0.81 | KDM4E (0.53) | KDM4EMAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL793083 | 0.80 | KDM4E (0.55) | KDM4EMAPTMAOB | |
| SCHEMBL933781 | 0.76 | KDM4E (0.51) | KDM4EMAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL1733676 | 0.75 | CYP19A1 (0.55) | KDM4EMAPTALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| EP-2451781-B1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| WO-2011004016-A1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | KDM4E 414/4885MAPT 2520/4885PARP10 2939/4885 |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | KDM4E 505/4885MAPT 2572/4885PARP10 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.